Page 13 - 《中国药房》2023年9期

药品零售企业网售处方药风险及对策研究
Δ

施能进 ，丁 静 ，王 刚 ，胡卫江 ，王 蓓 ，虞 敏 [1.浙江药科职业大学药商学院，浙江 宁波 315500；
2 #
5
3
1＊
1
4
2.浙江大学医学院附属杭州市第一人民医院药学部，杭州 310006；3.杭州市药品检查中心，杭州 310004；
4. 上药控股宁波医药股份有限公司，浙江 宁波 315000；5. 华东医药供应链管理（杭州）有限公司，杭州
310018]
中图分类号 R95 文献标志码 A 文章编号 1001-0408（2023）09-1031-07
DOI 10.6039/j.issn.1001-0408.2023.09.02

摘 要 目的 分析药品零售企业网售处方药风险，为网售处方药的风险防控提供对策建议。方法 采用层次分析法构建药品零
售企业网售处方药风险层次结构模型，再进行风险判断矩阵的归一化权重计算和一致性检验；采用德尔菲专家调查法对123对评
价指标进行多轮风险研判，开展模糊定量研究。结果 药品零售企业网售处方药风险中的处方调剂及审核风险（6.48%）、先药后方
风险（5.48%）、合理用药指导风险（4.99%）、非正常用途购买药品风险（4.97%）、“首诊、非慢性病、非常见病”风险（4.43%）、退货药
品质量安全风险（4.34%）、监管技术应用风险（4.06%）为高风险点；药品零售企业（连锁）网售处方药的总体风险为38.67%，药品零
售企业（单体）网售处方药的总体风险为61.33%，两者之间相差22.66%。结论 药品零售企业网售处方药高风险指标有7个，其中
处方调剂及审核风险、先药后方风险、合理用药指导风险为排名前3位的高风险点；药品零售企业（单体）网售处方药的风险要高
于药品零售企业（连锁）。建议监管部门重点关注并规范药品零售企业（单体）的网售处方药行为，鼓励药品零售企业（连锁）建立
系统的处方药网售流程；对于网售处方药的高风险点，建议监管部门和药品零售企业重点关注并采取有效风险防控措施，以保障
老百姓网购处方药的安全用药权益。
关键词 药品零售企业；网售处方药；风险；监管；单体；连锁

Study on the risk and countermeasure of prescription drugs sold online by drug retail enterprises
3
2
SHI Nengjin ，DING Jing ，WANG Gang ，HU Weijiang ，WANG Bei ，YU Min [1. School of Pharmaceutical
4
1
1
5
Business， Zhejiang Pharmaceutical Vocational University， Zhejiang Ningbo 315500， China；2. Dept. of
Pharmacy， Hangzhou First People’s Hospital Affiliated to Zhejiang University School of Medicine， Hangzhou
310006， China；3. Hangzhou Drug Inspection Center， Hangzhou 310004， China；4. SPN Ningbo Pharmaceutical
Co.， Ltd.， Zhejiang Ningbo 315000， China；5. East China Pharmaceutical Supply Chain Management
（Hangzhou） Co.， Ltd.， Hangzhou 310018， China]
ABSTRACT OBJECTIVE To analyze the risks of prescription drugs sold online by drug retail enterprises， and to provide

countermeasures and suggestions for risk prevention and control of prescription drugs sold online. METHODS The risk hierarchy
structure model of prescription drugs sold online by drug retail enterprises was constructed by using analytic hierarchy process.
Multiple rounds of risk research and judgment were carried out on 123 pairs of evaluation indicators by using Delphi expert survey
method. The normalized weight calculation and consistency test of risk judgment matrix were carried out to perform fuzzy
quantitative research. RESULTS The risk of prescription dispensing and review （6.48%）， the risk of drug first and prescription
later （5.48%）， the risk of rational drug use guidance （4.99%）， the risk of buying drugs by abnormal channel （4.97%）， the risk of
“first diagnosis， non-chronic disease and non-common disease” （4.43%）， and the quality and safety risk of returned drugs （4.34%）
and the application risk of regulatory technology （4.06%） were high risks； the overall risk of drug retail enterprises （chain） selling
prescription drugs online was 38.67%， and the overall risk of drug retail enterprises （individual） selling prescription drugs online
was 61.33%， with a difference of 22.66% between them. CONCLUSIONS There were 7 high-risk indicators for prescription drugs
sold online by drug retail enterprises. Among them， the risk of prescription dispensing and review， the risk of drug first and
prescription later， and the risk of rational drug use guidance
Δ 基金项目 浙江省哲学社会科学规划课题（No.20NDJC221YB）
are the top three high-risk points. The risk of prescription
＊第一作者 副教授，硕士。研究方向：药品经营与管理、药事管
理。电话：0574-88839045。E-mail：Shinj@mail.zjpc.net drugs sold online by drug retail enterprises （individual） is
# 通信作者 主 任 药 师 。 研 究 方 向 ：药 事 管 理 。 电 话 ：0571- higher than that of drug retail enterprises （chain）. It is
56007188。E-mail：88485534@163.com recommended that regulatory authorities focus on and regulate

中国药房 2023年第34卷第9期 China Pharmacy 2023 Vol. 34 No. 9 · 1031 ·